APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucagon Like Peptide-1 (GLP-1) Agonists

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Selected research

Market Outlook & Growth Opportunities

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook and Growth Opportunities 2026

25 December 2025195 pages

Choose your research edition.

Industry ResearchGlucagon Like Peptide-1 (GLP-1) Agonists Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Read the full market overview

This report provides an overview of the global Glucagon Like Peptide-1 (GLP-1) Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Glucagon Like Peptide-1 (GLP-1) Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Glucagon Like Peptide-1 (GLP-1) Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Company

Novo Nordisk

AstraZeneca

Eli Lily

GSK

Sanofi

Bristol-Myers Squibb

Amylin

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application

Hospital

Pharmacy

Other

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Glucagon Like Peptide-1 (GLP-1) Agonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Glucagon Like Peptide-1 (GLP-1) Agonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Glucagon Like Peptide-1 (GLP-1) Agonists significant trends, drivers, influence factors in global and regions.

6. To analyze Glucagon Like Peptide-1 (GLP-1) Agonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Glucagon Like Peptide-1 (GLP-1) Agonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glucagon Like Peptide-1 (GLP-1) Agonists industry.

Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Glucagon Like Peptide-1 (GLP-1) Agonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends Table 2. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers Table 3. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges Table 4. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Company (2021-2026) Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Company (2021-2026) Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Company Manufacturing Base & Headquarters Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company, Product Type & Application Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Exenatied Table 18. Significant Companies of Liraglutide Table 19. Significant Companies of Lixisenatide Table 20. Significant Companies of Albiglutide Table 21. Significant Companies of Dulaglutide Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2021-2026) Table 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2027-2032) Table 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2021-2026) Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Pharmacy Table 34. Significant Companies of Other Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2021-2026) Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2027-2032) Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2021-2026) Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2027-2032) Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2026) & (K Units) Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2021-2026) Table 48. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2027-2032) & (K Units) Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2027-2032) Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region (2021-2026) Table 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region (2027-2032) Table 55. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (USD/Unit) by Region (2021-2026) Table 56. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (USD/Unit) by Region (2027-2032) Table 57. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 60. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2026) Table 61. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 62. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2027-2032) Table 63. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Country (2021-2026) Table 65. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Country (2027-2032) Table 67. Novo Nordisk Company Information Table 68. Novo Nordisk Business Overview Table 69. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 70. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 71. Novo Nordisk Recent Development Table 72. AstraZeneca Company Information Table 73. AstraZeneca Business Overview Table 74. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 75. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 76. AstraZeneca Recent Development Table 77. Eli Lily Company Information Table 78. Eli Lily Business Overview Table 79. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 80. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 81. Eli Lily Recent Development Table 82. GSK Company Information Table 83. GSK Business Overview Table 84. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 85. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 86. GSK Recent Development Table 87. Sanofi Company Information Table 88. Sanofi Business Overview Table 89. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 91. Sanofi Recent Development Table 92. Bristol-Myers Squibb Company Information Table 93. Bristol-Myers Squibb Business Overview Table 94. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 96. Bristol-Myers Squibb Recent Development Table 97. Amylin Company Information Table 98. Amylin Business Overview Table 99. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 101. Amylin Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List Table 105. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Image Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2021-2032) & (K Units) Figure 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Exenatied Image Figure 10. Liraglutide Image Figure 11. Lixisenatide Image Figure 12. Albiglutide Image Figure 13. Dulaglutide Image Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2021-2032) Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Pharmacy Image Figure 22. Other Image Figure 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2021-2032) Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2021-2032) Figure 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032) & (US$ Million) Figure 34. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032) & (US$ Million) Figure 40. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatied
  • Liraglutide
  • Lixisenatide
  • Albiglutide
  • Dulaglutide
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Novo Nordisk
  • AstraZeneca
  • Eli Lily
  • GSK
  • Sanofi
  • Bristol-Myers Squibb
  • Amylin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032)
  4. 1.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (2021-2032)
  5. 1.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
  1. 2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
  2. 2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
  3. 2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
  4. 2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
3 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Company
  1. 3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Revenue Ranking in 2025
  2. 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2021-2026)
  3. 3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company (2021-2026)
  4. 3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Company (2021-2026)
  5. 3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Ranking (2024-2026)
  6. 3.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Manufacturing Base and Headquarters
  7. 3.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Product Type and Application
  8. 3.8 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Glucagon Like Peptide-1 (GLP-1) Agonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Type
  1. 4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Type Introduction
  2. 4.1.1 Exenatied
  3. 4.1.2 Liraglutide
  4. 4.1.3 Lixisenatide
  5. 4.1.4 Albiglutide
  6. 4.1.5 Dulaglutide
  7. 4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type
  8. 4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type
  12. 4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2021-2032)
  14. 4.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2021-2032)
5 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Application
  1. 5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application
  6. 5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application
  10. 5.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2021-2032)
  12. 5.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2021-2032)
6 Glucagon Like Peptide-1 (GLP-1) Agonists Regional Sales and Value Analysis
  1. 6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2032)
  3. 6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021-2026
  4. 6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2027-2032)
  5. 6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2027-2032)
  9. 6.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032)
  12. 6.6.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032)
  15. 6.7.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032)
  21. 6.9.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2025 VS 2032
7 Glucagon Like Peptide-1 (GLP-1) Agonists Country-level Sales and Value Analysis
  1. 7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  4. 7.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026)
  5. 7.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032)
  6. 7.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk
  2. 8.1.1 Novo Nordisk Company Information
  3. 8.1.2 Novo Nordisk Business Overview
  4. 8.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  6. 8.1.5 Novo Nordisk Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Eli Lily
  14. 8.3.1 Eli Lily Company Information
  15. 8.3.2 Eli Lily Business Overview
  16. 8.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  18. 8.3.5 Eli Lily Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Bristol-Myers Squibb
  32. 8.6.1 Bristol-Myers Squibb Company Information
  33. 8.6.2 Bristol-Myers Squibb Business Overview
  34. 8.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Recent Developments
  37. 8.7 Amylin
  38. 8.7.1 Amylin Company Information
  39. 8.7.2 Amylin Business Overview
  40. 8.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  42. 8.7.5 Amylin Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
  2. 9.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Mode & Process
  6. 9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
  9. 9.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst